Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights

Clin Exp Dermatol. 2024 Mar 21;49(4):392-394. doi: 10.1093/ced/llad387.

Authors

Ivan Rodriguez¹, Thomas Norman¹, Jana Guenther¹, Kimberly Smart¹, Andrew Kwong², Jesse Berry³, Gino K In⁴, Scott Worswick²

Affiliations

¹ Keck School of Medicine.
² Department of Dermatology.
³ Department of Ophthalmology.
⁴ Division of Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

PMID: 37956104
DOI: 10.1093/ced/llad387

No abstract available

MeSH terms

Humans
Melanoma* / pathology
Recombinant Fusion Proteins*
Skin Neoplasms* / drug therapy
Uveal Neoplasms* / drug therapy

Substances

tebentafusp
Recombinant Fusion Proteins

Supplementary concepts

Uveal melanoma